Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment-Reference-Cited by-同舟云学术

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment

Published:2013-10 Issue:4 Volume:59 Page:709-716
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Seto Wai-Kay,Liu Kevin,Wong Danny Ka-Ho,Fung James,Huang Fung-Yu,Hung Ivan Fan-Ngai,Lai Ching-Lung,Yuen Man-Fung

Publisher

Elsevier BV

Subject

Hepatology

Reference30 articles.

1. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B;Heathcote;Gastroenterology,2011

2. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues;van Bommel;Hepatology,2010

3. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B;Patterson;Gut,2011

4. No resistance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hepatitis B virus;Snow-Lampart;Hepatology,2011

5. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection;Chotiyaputta;J Viral Hepat,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial;Trials;2023-12-02

2. Effectiveness and Safety of Tenofovir Alafenamide in Treatment-Naïve and Treatment-Experienced Patients with Chronic Hepatitis B: Results of a Real-World Study from China;Hepatitis Monthly;2023-10-17

3. Trend patterns of HBsAg kinetics in chronic hepatitis B patients during nucleos(t)ide analogue therapy based on ARMA models;Journal of the Formosan Medical Association;2023-06

4. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL;Hepatology International;2022-03-24

5. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study;BMC Gastroenterology;2021-12